Pharma Focus Asia

Crysvita - A Breakthrough Therapy Developed For Treatment of TumorInduced Osteomalacia TIO

Crysvita (burosumab-twza) injection the first therapy discovered for the treatment of patients with rare disease, tumor-induced osteomalacia (TIO) corresponding to the age two and older.

The rare disease targets development of tumors that weakens and softened bones. TIO releases a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels.

FGF23 regulates levels of phosphate, an electrolyte plays important roles in bone maintenance, energy production by cells and nerve function. Insufficient phosphate in the body softens and weakens the bone resulting in osteomalacia (marked softening of bones).

Tumor-induced osteomalacia (TIO) treatment mainly works on identifying and removing the tumor that causes the spread of the disease.

Some of the side effects caused in adults with TIO taking Crysvitaare dizziness, tooth abscess (infection), muscle spasms, constipation, injection site reaction, rash and headaches.In addition, patients with severe kidney impairment or end stage renal disease should avoid taking Crysvita.

Crysvita, FDA approved first therapy for rare disease that causes low phosphate blood levels, bone softening is used for treatingadults and children six months and older with X-linked hypophosphatemia.

magazine-slider-imageMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference